Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAN-3
- Development stage
- Unknown
- Lead developer
- Protein Laboratories
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intraperitoneal, Parenteral
01
Overview
LAN-3 is a recombinant mouse leptin receptor antagonist containing the L39A/D40A/F41A mutations. Developed by Protein Laboratories Rehovot, it is a 16 kDa polypeptide chain consisting of 146 amino acids with an additional alanine at the N-terminus. LAN-3 acts as a highly specific and competitive antagonist of the leptin receptor, blocking leptin-induced signaling. It is widely used as a laboratory research tool to investigate the physiological roles of leptin in energy homeostasis, glucose metabolism, and cardiovascular regulation in rodent models.
- Other names
- Leptin Antagonist, Mousemouse leptin antagonist (mutant L39A/D40A/F41A)mouse leptin antagonist L39A/D40A/F41A
02
Targets
LEPR (Leptin receptor)
Beyond the preview
Go deeper on LAN-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAN-3.